Levi & Korsinsky, LLP announces that a CNTA class action lawsuit has been filed on behalf of investors who purchased Centessa Pharmaceuticals plc (CNTA) : (a) American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022. For more on the CNTA Lawsuit please contact us today.
According to the Centessa Pharmaceuticals plc lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(i) the Company’s product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan’s clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874’s clinical and commercial prospects while downplaying the drug’s safety issues; and (v) as a result, documents issued in connection with Centessa’s initial public offering and the Company’s public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.
If you suffered a loss in Centessa Pharmaceuticals plc you have until November 28, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.